The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be
| Study Name on ClinicalTrials.gov (link is external) |
A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects |
|---|---|
| Study Drug | FDL169 |
| Type of Study Drug | CFTR modulator |
| Study Title | A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Safety, Pharmacokinetics (PK) and Pharmacodynamics(PD) of FDL169 in Cystic Fibrosis (CF) Subjects Homozygous for the F508del-CFTR Mutation |
| Study Phase | 1 |
| Study Sponsor | Flatley Discovery Lab LLC |
|
https://clinicaltrials.gov/ct2/show/NCT03093714?term=FDL169-2015-04&rank=1 |
|
| Participating ECFS-CTN sites | Please contact ecfs-ctn@uzleuven.be for most recent sitelist |
| Age | 18 years and older |